Status:
UNKNOWN
Renal Impact of KAFTRIO in Mucoviscidose Population
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to describe the renal impact of Elexacaftor-Teacaftor-Ivacaftor, a triple modulator therapy of CFTR channel, in patients with cystic fibrosis. This new treatment acts on...
Eligibility Criteria
Inclusion
- Patient with cystic fibrosis
- More than 18 years old
- Eligible for KAFTRIO
Exclusion
- KAFTRIO contraindication
- Patient less than 18 years old
- Dialysis patient
- Pregnant woman
- Greffed patient
- Patient opposition to data collection
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06197490
Start Date
January 1 2022
End Date
December 31 2023
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Lyon Sud
Pierre-Bénite, France, 69310